Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TONIC-2 trial in metastatic triple-negative breast cancer
NL-OMON54994Phase 2Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Feb 2020
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in triple-negative breast cancer (TNBC) comparing Control: nivolumab alone with cisplatin induction followed by nivolumab (2 arms). Primary endpoint: Progression-free survival after 6 cycles of nivolumab. Started Feb 2020; status: recruiting.
02
Drugs
nivolumabcisplatin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NL-OMON54994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54994.